Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Baxter
McKinsey
Merck
Colorcon

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR IBANDRONATE SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ibandronate Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00082927 ↗ Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain Completed Cancer Research UK Phase 3 2003-04-01 RATIONALE: Ibandronate may be effective in reducing bone pain caused by metastatic cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether ibandronate is more effective than standard treatment with radiation therapy in treating metastatic bone pain. PURPOSE: This phase III randomized clinical trial is studying ibandronate to see how well it works compared to single-dose local radiation therapy in treating patients with localized metastatic bone pain.
NCT00127205 ↗ S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed Cancer and Leukemia Group B Phase 3 2005-07-01 RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
NCT00127205 ↗ S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed Eastern Cooperative Oncology Group Phase 3 2005-07-01 RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
NCT00127205 ↗ S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed National Cancer Institute (NCI) Phase 3 2005-07-01 RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
NCT00127205 ↗ S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed NCIC Clinical Trials Group Phase 3 2005-07-01 RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
NCT00127205 ↗ S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Completed North Central Cancer Treatment Group Phase 3 2005-07-01 RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ibandronate Sodium

Condition Name

Condition Name for Ibandronate Sodium
Intervention Trials
Breast Cancer 4
Metastatic Cancer 3
Hypercalcemia of Malignancy 2
Osteoporosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ibandronate Sodium
Intervention Trials
Breast Neoplasms 4
Neoplasm Metastasis 3
Neoplasms 2
Hypercalcemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ibandronate Sodium

Trials by Country

Trials by Country for Ibandronate Sodium
Location Trials
United States 23
United Kingdom 7
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ibandronate Sodium
Location Trials
Pennsylvania 2
New York 2
New Mexico 2
Michigan 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ibandronate Sodium

Clinical Trial Phase

Clinical Trial Phase for Ibandronate Sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ibandronate Sodium
Clinical Trial Phase Trials
Completed 5
Withdrawn 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ibandronate Sodium

Sponsor Name

Sponsor Name for Ibandronate Sodium
Sponsor Trials
National Cancer Institute (NCI) 3
Southwest Oncology Group 3
Eastern Cooperative Oncology Group 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ibandronate Sodium
Sponsor Trials
Other 11
NIH 3
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts
McKesson
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.